menu
    • menu
    [{"orgOrder":0,"company":"Interius BioTherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"INT2104","moa":"CD7","graph1":"Oncology","graph2":"Phase I","graph3":"Interius BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Interius BioTherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Interius BioTherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Interius BioTherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"INT2104","moa":"CD7","graph1":"Oncology","graph2":"Phase I","graph3":"Interius BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Interius BioTherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Interius BioTherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Interius BioTherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"INT2104","moa":"CD7","graph1":"Oncology","graph2":"Phase I","graph3":"Interius BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Interius BioTherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Interius BioTherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Interius BioTherapeutics","sponsor":"WuXi Advanced Therapies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Partnership","leadProduct":"INT2104","moa":"CD7","graph1":"Oncology","graph2":"Preclinical","graph3":"Interius BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Interius BioTherapeutics \/ Interius BioTherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Interius BioTherapeutics \/ Interius BioTherapeutics"},{"orgOrder":0,"company":"Interius BioTherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"INT2104","moa":"CD7","graph1":"Oncology","graph2":"Phase I","graph3":"Interius BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Interius BioTherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Interius BioTherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Interius BioTherapeutics","sponsor":"Kite Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Acquisition","leadProduct":"INT2104","moa":"CD7","graph1":"Oncology","graph2":"Phase I","graph3":"Interius BioTherapeutics","amount2":0.34999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.34999999999999998,"dosageForm":"Infusion","sponsorNew":"Interius BioTherapeutics \/ Kite Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Interius BioTherapeutics \/ Kite Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Interius BioTherapeutics

    Menu

    Interius BioTherapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Interius BioTherapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Interius BioTherapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INT2104

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Kite Pharma

                            Deal Size : $350.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Kite to Acquire Interius Biotherapeutics to Advance in Vivo Platform

                            Details : Kite will enhance its expertise in cell therapy by incorporating Interius’s integrating in vivo platform & also leverage pipeline, including INT2104, being evaluated for B cell malignancies.

                            Product Name : INT2104

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : $350.0 million

                            August 21, 2025

                            Lead Product(s) : INT2104

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Kite Pharma

                            Deal Size : $350.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Interius BioTherapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Interius BioTherapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INT2104

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Interius BioTherapeutics Announces Phase 1 Trial Expansion Approval in Europe

                            Details : INT2104 is a first-in-class gene therapy that delivers a CAR transgene to generate effector CAR-T and CAR-NK cells. It is being evaluated for the treatment of refractory/relapsing b-cell malignancies.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            January 07, 2025

                            Lead Product(s) : INT2104

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Interius BioTherapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Interius BioTherapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INT2104

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Interius Doses First Patient with in Vivo CAR Therapy for B-Cell Malignancies

                            Details : INT2104, is an off the shelf, investigational, IV gene therapy, targeting CD7-positive T & NK cells & delivers a CAR transgene to create effector CAR-T & CAR-NK cells for r/r B-cell malignancies.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            October 23, 2024

                            Lead Product(s) : INT2104

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Interius BioTherapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Interius BioTherapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INT2104

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety of INT2104 in Participants Aged 18 Years and Older Who Have B-cell Cancer That Came Back After Prior Tr...

                            Details : INT2104 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma, B-Cell.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            August 06, 2024

                            Lead Product(s) : INT2104

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Interius BioTherapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Interius BioTherapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INT2104

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Interius BioTherapeutics Receives HREC Approval for Phase 1 CAR Therapeutic Trial

                            Details : INT2104, is an off the shelf, investigational, IV gene therapy, targeting CD7-positive T & NK cells & delivers a CAR transgene to create effector CAR-T & CAR-NK cells for r/r B-cell malignancies.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            July 09, 2024

                            Lead Product(s) : INT2104

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Interius BioTherapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Interius BioTherapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INT2104

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : WuXi Advanced Therapies

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Interius BioTherapeutics Announces Successful Manufacturing Partnership with WuXi Advanced Therapies

                            Details : Through the partnership, Interius will leverage WuXi ATU's CTDMO platform for Good Manufacturing Process (GMP) manufacturing of Phase I clinical product and will advance INT-2104 in vivo CART program for B cell malignancies to the clinic.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            May 08, 2023

                            Lead Product(s) : INT2104

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : WuXi Advanced Therapies

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth